Adverse drug reactions in some African herbal medicine: literature review and stakeholders’ interview  by Kamsu-Foguem, Bernard & Foguem, Clovis
integr med res 3 ( 2 0 1 4 ) 126–132
Available online at www.sciencedirect.com
Integrative Medicine Research
journa l homepage: www. imr- journa l .com
Review Article
Adverse drug reactions in some African herbal
medicine: literature review and stakeholders’
interview
Bernard Kamsu-Foguema,∗, Clovis Foguemb
a Laboratory of Production Engineering (LGP), ENIT-INPT University of Toulouse, Tarbes Cedex, France
b Center for Smeel, Taste and Food Science (CSGA), UMR 6265 CNRS, UMR 1324 INRA, University of Burgundy,
Dijon, France
a r t i c l e i n f o
Article history:
Received 24 January 2014
Received in revised form
12 May 2014
Accepted 13 May 2014
Available online 23 May 2014
Keywords:
alternative medicines
complementary therapies
pharmacovigilance practice
toxicological risk assessment
traditional medicine
a b s t r a c t
Background: In view of the large consumption of herbal medicine in Africa countries, it
is likely that many adverse drugs reactions go unrecorded with either patients failing to
present to health services, or no pharmacovigilance analysis being made, or the analysis
not being reported centrally. This problem is of interest especially for those who are work-
ing in the general area of adverse drug reactions or stakeholders in the domain of herbal
medicine for considering safety issues.
Methods:Weare particularly interested in theway that the use of verywell-knownandhighly
valued plants is linked to the observation of adverse drug reactions in African countries. We
investigated, through a literature review and using the Internet (with a semantic search
strategy), some well-known or popular medicinal plants used in African herbal medicine
(AHM). Other information on the properties related to use, and characteristics of medicinal
plants was complemented by some interviews with stakeholders.
Results: Although substantial progress has been made in elucidating the mechanisms of
action of many drugs, the pharmacological actions of many medicinal plants are generally
notwell understood. The results of a literature review suggest that the reported adverse drug
reactions of herbal remedies are often due to a lack of understanding of their preparation
and appropriate use. The results of stakeholders’ interviews suggest that there is a growing
need to provide patientswith correct information about the herbalmedicines they consume.
Conclusion: An important aspect of herbal medicine is the correct, timely, and integrated
communication of emerging data on risk as an essential part of pharmacovigilance, which
could actually improve the health and safety of patients. This calls for improved collabo-
ration between traditional practitioners and modern healthcare professionals, researchers,
and drug regulatory authorities. In addition, there is a need for an adverse drug reactionreporting system to facil
events.
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Fig. 1 – The adopted information-gathering process for. Kamsu-Foguem and C. Foguem/Adverse drug reactions in African her
. Introduction
edicinal plants are important materials for the pharmaceu-
ical and cosmetic industries. Neglected since the discovery
f synthetic drugs, which can be produced in a wider scale,
here has been a resurgence of interest in plant medicines
n recent years. It is estimated that approximately half of all
ynthetic drugs have a natural origin.1 Any substance with a
ealing inﬂuence can also generate unwanted or adverse side
eactions. As with synthetic drugs, the quality, efﬁcacy, and
afety of medicinal plants must also be assured. There is a
on-negligible contribution of Africa to the world’s medicinal
lants’ stock. In effect, Africa provides approximately 60,000
f the world’s higher plant species and yet contributes < 8% of
he 1100 drugs placed on the market worldwide.2 Many plants
sed in herbal medicine provide valuable promising medical
olutions to some diseases [pathologies and infections], since
any medicinal plants are a source of new medicines and
herefore they have an essential role in medical research.3
frican traditional medicine is “the most economical and
vailable system of health care for a large number of the
frican population in rural and semi-urban areas.”4 African
erbal medicine (AHM) is a fundamental element of African
raditional medicine practices.
However, there are some challenges and opportunities in
he improvement of herbal medicine. The various adverse
rug reactions of herbalmedicine carrywith themspeciﬁc risk
actors which can lead to increased vulnerability to human
ealth difﬁculties. In recognition of the increasing possi-
ilities of purchasing medicinal products on the street or
nline worldwide, improvement measures are needed to bet-
er inform people about the efﬁciency and vulnerabilities of
urchasing medicines. An adverse drug reaction is deﬁned by
dwards andAronson as “an harmful or troublesome reaction,
ue to intervention related to the use of a healing substance,
hich envisages risk from future administration and requires
revention or explicit treatment, or alteration of posology
nd method of administration, or withdrawal of the medical
ubstance.”5 The latency period between the use of a drug and
he occurrence of an adverse reaction can help in its causality
ssessment in pharmacovigilance management.6 Such infor-
ation can be invaluable in the interpretation of drug safety
ignals, and facilitate decisions on further protective actions
eing taken then and the type of further investigations about
lteration in the posology, or removal of the substance.
. Methods
e researched some well-known or popular AHM products
y using a literature review and through the Internet (using a
emantic search strategy).
A thorough literature search was made by referring to
ooks, peer-reviewed papers, scientiﬁc databases such as Sco-
us, Science Direct, PubMed, and Google Scholar. Keywords
uch as adverse drug reactions, African traditional medicine,
erbal or natural products, alternative therapy, surveillance,
hytotherapy in relation to medicinal plants were the terms
mployed in the different semantic investigations. Otherherbal practices.
information on the properties of medicinal plants was com-
plemented by interviews with stakeholders. Medicinal plants
were identiﬁed based on their traditional use in different
aspects of African traditional medicine.
In our approach, the information-gathering process was
based both on the details of stakeholders’ interviews and the
outcomes of the literature review. More speciﬁcally, in order
to obtain information about herbal practices and their associ-
ated effects, wewent through the following processwith three
phases adapted from Kamsu-Foguem et al7 (Fig. 1):
• Contact with African traditional health practitioners: develop-
ment of a trust-based relationship with African traditional
health practitioners for effective communication and
knowledge elicitation. Trust is especially necessary for open
and operative communication, since health practitioners
keep their knowledge secret and do not wish to share their
know-how outside the family environment.
• Collection of information about herbal practices: the infor-
mation is collected through questionnaires or structured
interviews with stakeholders. The form includes the fol-
lowing information for considered herbal medicines: type
of plant (tree, herb, parasite, shrub, liana or aqueous plant),
preparation of remedy (plant part, fresh, dried), dose and
regimen, disease or symptoms treated.
• Literature survey with monographs, chemical abstracts and
MEDLINE: we investigated the previously described medic-
inal uses of the plants, substances isolated and identiﬁed
pharmacological effects (medicinal properties, alternative
options for the use of the plant, and adverse effects).
3. Results
Our review as such was limited to highlighting the potential
for adverse drug reactions in AHM. Thus, we have consid-
ered that it is essential to clearly delimit the scope of the
study, which has been restricted to certain well-known and
highly appreciated plants in AHM. The rich ﬂora of Africa
(e.g., the Paleotropical natural environment of Central Africa
and the Capensis natural environment of South Africa) con-
tains numerous toxic plants with ethnopharmacological uses
(e.g., parasitic, bacterial, fungal or viral treatments, treatment
of central nervous system-related conditions, aphrodisiacs,
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and for maternal health care, miscellaneous conditions such
as cancer, arthritis, and heart conditions). Toxic constituents
(e.g., neurotoxins, cytotoxins, and metabolic toxins) from
these plants can harm the major systems of the human body
(cardiovascular system, digestive system, endocrine system,
urinary system, immune system, muscular system, nervous
system, reproductive system, and respiratory system).8
Several causality assessment methods have been proposed
to assess the relationship between drugs and the appearance
of adverse events. Those methods belong to three categories:
expert judgment, probabilistic methods, and algorithms or
scales.9 In view of their attractive characteristics (succes-
sive evaluation of criteria, sum of scores or decision trees),
scales and algorithms are usually used for operational assess-
ments of adverse drug reactions and they enable an easy and
convenient handling in various situations. For instance, the
Council for International Organizations of Medical Sciences
(CIOMS) scale, also referred to as the Roussel Uclaf Causal-
ity Assessment Method (RUCAM),10 is used by many expert
hepatologists, researchers, and regulatory authorities to eval-
uate the possibility of supposed underlying causes of adverse
drug reactions. Particularly, the CIOMS provides advantages
[standardized scale (chronology, risk factors, concomitant
drug(s) or herbs(s), search for nondrug/herb causes, previous
information on hepatotoxicity of the drug/herb, response to
unintentional readministration), validation for hepatotoxicity
with excellent sensitivity, speciﬁcity, and predictive validity]
for drug-induced liver injury and herb induced liver injury
(HILI) causality assessment.11 Meanwhile, the CIOMS scale
has certain weaknesses (e.g., retrospective use, dechallenge
criteria, qualitatively graded risk factors, and limited exclu-
sion of alternative causes). Some challenges (e.g., the quality
of adverse reaction reports) inﬂuence the accuracy in causal-
ity assessment of herbal medicinal products. The exploration
of omics technologies (genomics/transcriptomics, proteomics,
and metabolomics) applied to toxicology (toxicogenomics,
toxicoproteomics, and toxicometabolomics) is a valuable way
of providing additional information related topredictive safety
assessment of herbal medicinal products.12 The predictive
toxicity of herbal constituents generates emerging opportu-
nities that are essential to improve the knowledge base for
integrated safety assessment.
The results are presented in two segments, one on the lit-
erature review and the other on the stakeholders’ interview.
We obtained 100 reports from the literature review and > 50
stakeholders’ interviews. This research took place over a 2-
year period from December 2012 to January 2014.
• The literature review conducted in the area of AHM only
reported adverse drug reactions often a negligible impact
on the global health issues in a country or region. How-
ever, people are very often subject to safety risks related
to herbal medicine which affect or may affect their vital
organs (e.g., kidneys, lungs, liver, gastrointestinal tract) and
could cause serious damage to other vulnerable areas of the
human body. The survey reveals that adverse drug reactions
may be caused by logistical and technical problems or ques-
tionable decisions by the traditional health practitioners.
The logistical and technical problems include poor har-
vest, the inadequate identiﬁcation of complex properties,Integr Med Res ( 2 0 1 4 ) 126–132
inappropriate preparation, improper conservation or incor-
rect packing of natural products. The considered problems
are not peculiar to the selected plants alone, but exist also
in other herbal medicine products that are not included in
this study, because of the nonexhaustive nature of the list of
products encountered in AHM. Furthermore, a certain con-
trol range can be made to monitor the widespread practice
of combining many different compound classes and herbal
types or creating heterogeneous product class models for
use in therapeutic procedures.
• The stakeholders’ interview results in signiﬁcant informa-
tion that has highlighted (in addition to managerial and
some regulatory problems) insufﬁcient communication in
relation to increased consumption of products from AHM.
Traditional health practitioners are capable of identify-
ing simple adverse drug reactions and taking preventive
actions by learning ideas with experienced feedback pro-
cesses. Meanwhile, for complex adverse drug reactions, the
lack of apparent symptoms, coupled with the potential to
cause severe damage to key organs, means that educational
assistance for careful and safe use of herbalmedicinal prod-
ucts must be encouraged, with special care for high-risk
patients. The problem is typically manifested by the fact
that information is often either inaccessible, incomplete,
or of low quality about potential adverse drug reactions of
used herbal products. The managerial and regulatory bar-
riers are present in many African countries by the lack of
clear enforced rules for bearing and sharing various expe-
rienced feedback processes, as well as by the absence of
systems that can help to promote integrative policies and
implementation.
Examples of potential adverse effects of some herbal
medicines with their traditional use and their countries of
origin are presented in Table 1.
4. Discussion
Quality of herbal medicines is a matter that affects the whole
world today, with a requirement for the safety monitoring of
herbal remedies, and there is a growing necessity to provide
consumers with the correct information about the medicinal
products they consume. In this perspective, quality control of
herbal medicine and good practices are indispensable for the
advancement of the herbal medicine system.24 Quality prob-
lems of herbal medicines can be categorized into two classes:
internal factors arising from the drug and external factors
in clinical use.25 The internal safety factors related to drug
quality include: raw herbals (species and origin, place of ori-
gin and collection, natural environment, processing, storage),
inactive ingredients, manufacturing, defects of the prescrib-
ing information/package leaﬂet, limitations of premarketing
safety studies, and adulterated and counterfeit drugs. The
external safety factors in clinical use comprise: lack of tradi-
tional medicine theoretical guidance, failure to adhere to the
prescribing information, inappropriate combinationwith allo-
pathic medicines, inappropriate route and dosing and timing,
incorrect preparation, and individual factors.
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Table 1 – Examples of medicinal plants with their potential adverse drug reactions.
Medicinal plants Traditional uses Potential adverse effects Origin
Pygeum africanum
(Prunus africana)
Prostate cancer, prostatitis, benign
prostatic hyperplasia, other
urinary tract infections, and
aphrodisiac
Gastrointestinal upsets13 Cameroon, South Africa,
and Madagascar
Wild wisteria, violet
tree (Securidaca
longepedunculata)
Laxative, nervous system ailments
(epilepsy), wounds, sores, coughs,
venereal diseases, snakebites,
bilharzias, headaches, fever
related to malaria, erectile
dysfunction or aphrodisiac,
dysmenorrhea, and abortion
induction
Acute kidney (cortical necrosis,
acute interstitial nephritis), injury,
diarrhea, dehydration, and
collapse14
Tanzania, Malawi, Soudan,
Burkina Faso, Congo,
Zambia, and Zimbabwe
Madagascar rosy
periwinkle
(Catharanthus
roseus)
Cancer chemotherapy Medullary aplasia, leucopoenia,
incoordination of movements,
convulsions, fatigue, mucositis,
constipation, and neutropenia of
short duration15
Madagascar
Round leaf Buchu
(Agathosma
betulina)
Diuretic and urinary tract
antiseptic, arthritis, treatment of
cellulite, cystitis, diarrhea,
ﬂatulence, kidney infections,
nausea, rheumatism, and wounds
Gastrointestinal irritation, and
centrilobular hepatic or
hepatocellular necrosis16
South Africa
Umckaloabo or
South African
Geranium
(Pelargonium
sidoides)
Coughs, upper respiratory tract
irritations and infections
(bronchitis, sinusitis, and
pneumonia, tonsillitis, and
rhinopharyngitis), gastrointestinal
disorders, and pain
Gastrointestinal complaints
(nausea, heartburn, diarrhea), skin
rashes, and allergic
(hypersensitivity) reactions17
South Africa
Hoodia cactus
(Hoodia gordonii)
Appetite suppressant and
anorectic action
Potentiation of diabetes mellitus
(hyperglycemia), sometimes
hypoglycemia and confusions18
South Africa and Namibia
Red spinach (also
known as Chinese
spinach,
Hon-toi-moi, Yin
choy, Hsien tsai) or
Spleen amaranth
(Amaranthus
dubius)
Diuresis [high blood pressure,
kidney infections, obesity, and the
edema associated with
premenstrual syndrome (PMS) or
traumatic injuries]
Hypotension, skin irritations, to
extensive organ and tissue
damage with death induction19
Africa (e.g., Ethiopia, South
Africa, Kenya, and Uganda),
Asia, India, Europe, West
Indies, North America, and
South America
Bird ﬂower
(Crotalaria
laburnifolia)
Dysmenorrhea and abortion
induction20
Acute kidney injury, hepatic
veno-occlusive disease, pulmonary
injury, and thrombocytopenia
Africa (e.g., Zimbabwe) and
Asia (e.g., Sri Lanka)
Impila, ox-eye daisy
(Callilepis laureola)
Impotence, evil spirits, and
gastrointestinal complaints21
Chronic renal disease, acute
kidney injury, hyperkalemia,
abdominal pain, vomiting,
diarrhea, a disturbed level of
consciousness, convulsions, and
liver failure
North and South Africa,
and Mediterranean Basin
Khat leaf (Catha
edulis)
Central stimulant action (e.g.,
management of obesity and
depression)22
Chronic kidney disease, acute
kidney injury (acute tubular
necrosis), hepatotoxicity,
cardiovascular diseases
(hypertension, cerebrovascular
ischemia, dilated cardiomyopathy,
myocardial infarction, and
thromboembolism), diabetes,
sexual dysfunction, duodenal
ulcer, and hepatitis
East Africa, Yemen
Licorice (Glycyrrhiza
glabra)
Sore throat, cough, arthritis, and
weight loss induction23
Acute kidney injury (hypokalemic
nephropathy), amenorrhea,
pseudoaldosteronism,
hypertension, heart failure, and
rhabdomyolysis
Worldwide
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African regions are particularly concerned by these issues
requiring an adverse drug reaction reporting system to reduce
the risks of AHM. However, few African countries (e.g., South
Africa, Nigeria, and Cameroon) have subsequently introduced
herbal/traditionalmedicineaspart of their pharmacovigilance
system. South Africa has a well-built plant biotechnology
community, as well as the thorough implementation of a
legal and operational framework for the guideline of the
manipulation of local botanic resources, and of genetically-
modiﬁed organisms to improve human health.26 Nigeria is
in a position to introduce advanced investigations (assess-
ment of traditional medicine practitioners’ disposition and
doctors’ attitudes) which effectively explore the opportunities
for the integration of herbal medicine into the national health
system with applicable regulations.27,28 In Cameroon, the gov-
ernment, in collaboration with the World Health Organization
(WHO), has set up a strategic platform for the harmonization
of the AHM practices with an organizational framework that
has integrated a national commission specializing in pharma-
covigilance and traditional pharmacopoeia.3
There are also other regions of the world (e.g., China,
South Paciﬁc, and India) with some problems related to
herbal adverse drug reactions. The characteristics of tradi-
tional Chinese medicine drugs and their associated adverse
drug reactions require an accurate understanding of local
cultural and social realities in order to establish a stringent
quality control and a risk management model adapted to the
pharmacovigilance system (current practice, risk factors, risk
control, and future) inChina.29 In this context, a recent toxicity
evaluation (risk–beneﬁt analysis, severity of toxic effects, and
clinical and preclinical data) of Chinese herbal medicines has
led to the proposition of four regulatory classes: prohibited for
medicinal usage (e.g., aristolochia); restricted for medicinal
usage, (e.g., ephedra); required warning label (e.g., coltsfoot);
and over-the-counter herbs (i.e., safe toxicity proﬁles).30 In the
South Paciﬁc, we found the kava plant (Piper methysticum) con-
sumed worldwide for its relaxing properties and used to treat
general anxiety. Traditional aqueous extracts of this paciﬁc
herb used in New Caledonia, Australia, the USA, and Germany
are associated with rare hepatotoxicity. The primary cause of
the kava problem with this toxicity can be traced to poor qual-
ity of the raw material triggered by mold hepatotoxins.31–33
In the worldwide cases, the organs most notably affected
by herbal medicine consumption are the liver and kid-
neys, as they functionally detoxify and excrete several toxic
substances including metabolic wastes. Many renal syn-
dromes have been reported following the use of medicinal
plants, including tubular necrosis, acute interstitial nephritis,
Fanconi’s syndrome, hypokalemia or hyperkalemia, hyper-
tension, papillary necrosis, chronic interstitial nephritis,
nephrolithiasis, urinary retention, and cancer of the urinary
tract.34 A recent United States research study, completed by
the Einstein Medical Center, Philadelphia, reported that the
use of herbal and dietary supplements (HDS) has a devastating
impact on consumers’ quality of life, as they begin to damage
the liver irreversibly and this requires a relevant clinical per-
35spective to the diagnosis of HDS-induced liver injury (HILI).
In fact, herbal and dietary supplements are generally used
throughout the world. There is a large and varied quantity of
herbal medicinal products (e.g., Ayurvedic and Chinese herbs,Integr Med Res ( 2 0 1 4 ) 126–132
black cohosh, chaparral, germander, greater celandine, green
tea, Herbalife, Hydroxycut, kava, pennyroyal, pyrrolizidine
alkaloids, skullcap, and usnic acid), which are associated
with a range of hepatotoxicity events.36–42 Progress in the
understanding of the epidemiology of induced cell and organ
injuries, the pathogenesis, clinical observations, and conse-
quences is required to be able to advance herbal medicine
safety.
5. Conclusion
In both developed and developing countries, self-medication
and consulting community networks for many herbal
medicines tend to decrease monitoring of treatment adher-
ence, as do adverse effects, which patients may not always
mention. More speciﬁcally, the African reality clearly shows
that natural products are perceived as safe and secure with
herbal medicines at sustainable low prices. In general, AHM
products have some potential side effects (dose-related, time-
related, or failure of therapy) that can damage a basic
structural, functional, and biological unit of the organism,
such as a cell (cytotoxicity) or an organ such as the kid-
ney (nephrotoxicity) or the heart (cardiotoxicity) or the liver
(hepatotoxicity). Particularly, the studied medicinal plants can
cause problems in some systems of the human body (e.g., car-
diovascular system, digestive system, and nervous system).
Thus, with our research sample (Pygeum africanum, wild wis-
teria, Madagascar rosy periwinkle, round leaf Buchu, South
African geranium, Hoodia cactus, red spinach, bird ﬂower,
Impila, ox-eye daisy, khat leaf, and licorice), we have noticed
some adverse drug reactions with several clinical manifes-
tations of toxic effects of plants that cause gastrointestinal,
respiratory, cardiovascular, and neurological disorders.
Despite their lack of knowledge of physiopathology and
physiomolecular processes, traditional medicine practition-
ers often possess information and experienced knowledge
that is not yet widely or universally known and insufﬁciently
used. However, these practitioners should be equipped with
adequate knowledge of the pharmacological properties of
medicinal plants to be able to serve as a guide for them to
easily identify the information needed for the interpretation
of adverse medical effects and counselling patients. Although
many important plants of Africa with ethnopharmacological
uses couldhavepotential biological activities, there are anum-
ber of the active principles (e.g., alkaloids, cardiac glycosides,
phorbol esters, lectins, and cyanogenic glycosides) in these
medicinal plants that are extremely toxic. Finally, medic-
inal substances in the African traditional pharmacopoeia
must comply with the international Pharmacopoeia and WHO
recommendations, to offer good quality products and safe
services. These improvements would have a considerable
compact on the physical, mental, and social beneﬁts of tra-
ditional medicine in development of both preventative and
therapeutic health care services to patients in the ﬁeld of inte-
grative medicine.Conﬂicts of interest
All authors declare no conﬂicts of interest.
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